Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study.
A multicentric study of prenatal treatment of congenital adrenal hyperplasia (CAH) resulting from 21-hydroxylase deficiency in 43 pregnancies at risk for CAH is presented. The mothers were given dexamethasone per os, 0.5 mg either 12-hourly or 8-hourly. From the analysis of the results obtained in the present study and review of the literature, it would appear that the first condition for successful prevention of female virilization in utero (a total of 6 cases) is to start treatment as early as possible, no later than the 7th week. The dose of dexamethasone should be related to maternal size: 20 micrograms/kg/day (in 2 or 3 fractioned) doses would seem to be both efficient and safe. Adrenal suppression of both maternal and fetal adrenal function should be controlled by appropriate hormonal determinations. Finally, the advantages of early prenatal diagnosis or no prenatal diagnosis are discussed.
Forest
M G
MG
INSERM U 34, Hôpital Debrousse, Lyon, France.
Bétuel
H
H
David
M
M
D000312:Adrenal Hyperplasia, Congenital / Q000175:diagnosis / Q000188:drug therapy* / Q000196:embryology; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D005602:France; D006580:Genetic Carrier Screening; D006801:Humans; D008431:Maternal-Fetal Exchange; D015337:Multicenter Studies as Topic; D011247:Pregnancy; D011296:Prenatal Diagnosis; D013250:Steroid Hydroxylases / Q000172:deficiency*
D003907:Dexamethasone; D013250:Steroid Hydroxylases